Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
ZB-H Zions Bancorp
BSM Black Stone Minerals LP
ZIONZ Zions Bancorp *W EXP 11/14/2018
PRENU Prairie Ethanol LLC
DXTR Dextera Surgical Inc
XDSUX BlackRock Debt Strategies Fund Inc
CPT.BAT Camden Property Trust
BPMX Biopharmx Corp
JVA Coffee Holding Co Inc
Go

Health Care : Biotechnology | Large Cap GrowthCompany profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Closing Price
$147.41
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
148.79
Day's Low
146.65
Volume
(Light)
Volume:
903,595
10-day average volume:
1,229,347
903,595
  • Prev Close
    147.41
  • Today's Open
    147.70
  • Day's Range
    146.65-148.79
  • Avg Vol (10-day)
    1.2M
  • Last (time)
    4:15p ET 11/17/17
  • Last (size)
    2
  • 52-Wk Range
    71.46 - 167.86
    LowHigh
  • (12/22/16 - 07/25/17)
    12.18%
  • 38.0%
  • Market Cap
    37.3B
  • Shares Outstanding
    252.9M
  • 0.78
  • 188.93x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.6
  • 95.44
  • (% of float 10/31/17)
    1.38

Latest News

November 15, 2017
1:01 pm ET
Globe Newswire
November 10, 2017
12:30 pm ET
BusinessWire
November 10, 2017
11:50 am ET
PR Newswire
November 03, 2017
3:00 pm ET
BusinessWire
November 03, 2017
2:34 pm ET
BusinessWire
November 02, 2017
8:01 pm ET
BusinessWire
November 01, 2017
12:30 pm ET
BusinessWire
October 26, 2017
7:46 pm ET
MarketWatch
October 25, 2017
8:01 pm ET
BusinessWire
October 24, 2017
3:51 pm ET
MarketWatch
October 23, 2017
12:32 pm ET
BusinessWire
October 17, 2017
10:15 am ET
BusinessWire
October 16, 2017
8:01 pm ET
BusinessWire
October 16, 2017
6:31 pm ET
MarketWatch
October 02, 2017
7:30 pm ET
MarketWatch
September 28, 2017
11:10 am ET
PR Newswire
September 19, 2017
2:50 pm ET
BusinessWire
September 18, 2017
4:29 pm ET
MarketWatch
September 07, 2017
8:01 pm ET
BusinessWire
September 06, 2017
12:29 pm ET
MarketWatch
September 06, 2017
12:19 pm ET
MarketWatch
September 06, 2017
12:05 pm ET
BusinessWire
August 30, 2017
1:00 pm ET
Globe Newswire
August 24, 2017
12:30 pm ET
BusinessWire
August 16, 2017
1:39 pm ET
MarketWatch
August 08, 2017
10:56 am ET
MarketWatch
July 31, 2017
11:33 am ET
MarketWatch
July 19, 2017
1:57 pm ET
MarketWatch
July 19, 2017
12:00 pm ET
MarketWatch
July 19, 2017
10:52 am ET
MarketWatch
July 19, 2017
10:51 am ET
MarketWatch
July 19, 2017
10:20 am ET
MarketWatch
July 18, 2017
10:19 pm ET
MarketWatch
July 18, 2017
8:23 pm ET
MarketWatch
July 17, 2017
12:57 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2017. All rights reserved.